<DOC>
	<DOCNO>NCT00732368</DOCNO>
	<brief_summary>This study examine safety effectiveness long-term administration mometasone nasal spray patient perennial allergic rhinitis . Patients receive mometasone 12 week plus additional 12 week patient agree continue . Dose mometasone could decrease increase study base patient 's response .</brief_summary>
	<brief_title>A Long-term Study Mometasone Furoate Patients With Perennial Allergic Rhinitis ( Study P04459 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Moderate severe perennial allergic rhinitis , &gt; 16 year age Patients coexist tuberculous disease lower respiratory tract infection patient acute upper respiratory tract infection , acute pharyngolaryngitis , acute tonsillitis judge investigator require treatment Patients coexist infection systemic mycosis effective treatment Patients coexist mycosis nasal paranasal cavities Patients judge require prohibit concomitant drug clinical study Patients experience recent nasal septum ulcer , nasal surgery , nasal trauma , yet heal Patients history hypersensitivity steroids mometasone furoate Patients pregnant nursing may pregnant patient whose partner desire become pregnant study period Patients severe hepatic disorder , renal disorder , cardiac disease , diabetes mellitus , hypertension , hematological disease serious coexisting disease whose general condition poor judge investigator . Patients allergic pollen pollen release season occur 7 day start treatment Patients diagnose vasomotor rhinitis eosinophilic rhinitis Patients nasal condition may interfere efficacy evaluation study drug Patients develop disease may affect nasal symptom 7 day start treatment Patients participate participate clinical trial investigational drug within 120 day day obtain informed consent Patients period discontinuation previous treatment start study drug administration indicate Table 2 adequate avoid use drug Patients undergo specific desensitization therapy nonspecific allassotherapy ( Histaglobin , vaccine therapy , etc . ) discontinue therapy within 90 day prior obtain inform consent . ( However , patient need exclude therapy ongoing least 180 day obtain informed consent maintenance therapy conduct . )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>